医美概念股(BK1593)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BK1593 医美概念股

已收盘 12-15 16:00:00

1,164.264

-40.401

-3.35%

最高1,205.160	最低1,157.556	成交量6,448万
今开1,205.160	昨收1,204.665	日振幅3.95%
总市值0.00	流通市值0.00	总股本0.00
成交额11.87亿	换手率--	流通股本0.00
市净率1.77503	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"BK1593","market":"HK","secType":"PLATE","nameCN":"医美概念股","latestPrice":1164.2644,"timestamp":1765786113871,"preClose":1204.6652,"halted":0,"volume":64477604,"delay":0,"changeRate":-0.033537,"floatShares":0,"shares":0,"eps":0,"marketStatus":"已收盘","change":-40.400757,"latestTime":"12-15 16:00:00","open":1205.1598,"high":1205.1598,"low":1157.5562,"amount":1187298453,"amplitude":0.039516,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1765848600000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1765762200000,1765771200000],[1765774800000,1765785600000]],"pbRate":1.77503,"peRate":25.662118,"increases":0,"decrements":0,"flats":0},"requestUrl":"/m/hq/s/BK1593/tweets","defaultTab":"tweets","newsList":[{"id":"2591264308","title":"康哲药业(00867)：创新药口服小分子JAK1抑制剂Povorcitinib 纳入突破性治疗品种名单","url":"https://stock-news.laohu8.com/highlight/detail?id=2591264308","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591264308?lang=zh_cn&edition=full","pubTime":"2025-12-15 19:49","pubTimestamp":1765799362,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康哲药业 发布公告，集团旗下德镁医药有限公司拥有相关许可权利的创新口服JAK1抑制剂povorcitinib已获中国国家药品监督管理局药品评审中心批准纳入突破性治疗品种名单，拟定适应症为成人患者非节段型白癜风。Povorcitinib目前正在海外若干国家进行非节段型白癜风、中重度化脓性汗腺炎和结节性痒疹的3期临床试验。本次该产品获纳入突破性治疗药物品种名单，有望加速其在中国大陆的研发与审评进程。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1381734.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["00867","BK1574","SG9999015952.SGD","IE00BMCWC346.EUR","BK1191","IE00BVYPNQ40.USD","SG9999015945.SGD","SG9999004220.SGD","LU2488822045.USD","IE00BYV24P56.USD","IE00BVYPNP33.GBP","SG9999015978.USD","IE00BGHQDM52.EUR","159992","06978","SG9999015986.USD","BK1593","BK1161"],"gpt_icon":0},{"id":"2591648625","title":"争议药物\"九期一\"获新生？复星医药14亿元收购绿谷医药重启临床与商业化","url":"https://stock-news.laohu8.com/highlight/detail?id=2591648625","media":"蓝鲸财经","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591648625?lang=zh_cn&edition=full","pubTime":"2025-12-15 18:51","pubTimestamp":1765795877,"startTime":"0","endTime":"0","summary":"此次收购案后，复星医药方面表示，甘露特钠胶囊重新开展商业化生产和销售前，还需补充完成目前尚在开展的上市后确证性临床试验并获得国家药品审评部门批准。本次收购完成后，复星医药将携绿谷医药团队在药品审评部门的指导下，有序严谨推进上市后确证性临床试验，以期尽快实现获批；并适时开展相关适应症的国际多中心临床试验，惠及更多阿尔茨海默病患者。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1765795546434638047","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK0183","BK0175","BK0188","BK1191","BK1515","BK0028","BK0187","BK0196","BK0060","BK1593","BK0012","600196","09939","BK1161","02196","BK0096","BK1574","BK0239","159938"],"gpt_icon":0},{"id":"2591612068","title":"复星医药：控股子公司拟出资14.12亿元投资绿谷医药","url":"https://stock-news.laohu8.com/highlight/detail?id=2591612068","media":"每日经济新闻","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591612068?lang=zh_cn&edition=full","pubTime":"2025-12-15 17:43","pubTimestamp":1765791813,"startTime":"0","endTime":"0","summary":"每经AI快讯，12月15日，复星医药(600196.SH)公告称，公司控股子公司复星医药产业拟出资共计14.12亿元投资绿谷医药，包括受让部分股权和认缴新增注册资本。完成后，公司将通过复星医药产业及SPV合计持有绿谷医药53%的股权。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512153591807093.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512153591807093.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1593","BK1191","BK0012","BK0096","BK1574","BK1515","09939","BK0060","BK0188","BK0175","BK0239","BK0196","600196","BK0183","BK0187","BK0028","02196","159938","BK1161"],"gpt_icon":0},{"id":"2591936666","title":"智通决策参考︱关注地产和消费端能否找到发力点","url":"https://stock-news.laohu8.com/highlight/detail?id=2591936666","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591936666?lang=zh_cn&edition=full","pubTime":"2025-12-15 09:05","pubTimestamp":1765760744,"startTime":"0","endTime":"0","summary":"国内政策对冲关键在于地产和消费端能否找到发力点。相关个股值得关注。Suisselle成立于2021年，核心产品CELLBOOSTER系列水光针是全球首款获得CE认证的稳定复合型水光针，同步布局三文鱼针剂以及外泌体等细胞治疗产品领域。2，童颜针&少女针产品获批或快速放量。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1381329.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HSI","00460","MCHmain","01725","513600","BK1593","HHImain","BK1191","02833","BK1167","BK1600","02357","BK1515","BK1211","MHImain","BK1589"],"gpt_icon":0},{"id":"2591663764","title":"斥资近4000万押注连亏企业，昊海生科业绩承压下“赌”新赛道","url":"https://stock-news.laohu8.com/highlight/detail?id=2591663764","media":"北京商报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591663764?lang=zh_cn&edition=full","pubTime":"2025-12-14 18:30","pubTimestamp":1765708205,"startTime":"0","endTime":"0","summary":"继完成对新产业眼科的全资控股后，昊海生科又出手了。更为关键的是，本次交易未设置任何业绩承诺或对赌安排。2024年，昊海生科虽创下营收26.98亿元、归母净利润4.2亿元的历史最佳业绩，但增速已明显乏力，营收与净利润同比仅分别微增1.64%和1.04%。进入2025年，其业绩持续下滑。医药行业分析师朱明军表示，昊海生科并购瑞济生物是业绩承压下的战略补位，生物羊膜赛道的增长潜力与业务协同性值得肯定，但风险同样不容忽视。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251214183239a449d95c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251214183239a449d95c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","06826","BK1593"],"gpt_icon":0},{"id":"2591650118","title":"昊海生物科技(06826.HK)12月12日耗资112.38万港元回购4.23万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2591650118","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591650118?lang=zh_cn&edition=full","pubTime":"2025-12-14 16:37","pubTimestamp":1765701422,"startTime":"0","endTime":"0","summary":"格隆汇12月14日丨昊海生物科技(06826.HK)发布公告，2025年12月12日耗资112.38万港元回购4.23万股，回购价格每股26.5-26.64港元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20251214/31864601.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["06826","BK1593","BK1161"],"gpt_icon":0},{"id":"2591865967","title":"复星医药控股子公司酮洛芬贴剂获准开展III期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2591865967","media":"中金财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591865967?lang=zh_cn&edition=full","pubTime":"2025-12-14 08:13","pubTimestamp":1765671185,"startTime":"0","endTime":"0","summary":"中访网数据 上海复星医药(集团)股份有限公司于2025年12月12日发布公告，其控股子公司上海朝晖药业有限公司研发的酮洛芬贴剂，已获得国家药品监督管理局批准，将在中国境内开展III期临床试验。　　该事件的影响范围主要集中于复星医药集团及其控股子公司朝晖药业的研发管线推进，以及未来潜在的非甾体抗炎药外用贴剂市场。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251214/31864526.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0196","600196","BK0239","BK0187","BK0012","BK0060","BK0188","BK1191","BK4134","BK0096","BK0183","III","02196","BK1515","BK0175","BK0028","BK1593"],"gpt_icon":0},{"id":"2591594657","title":"30亿+首仿，复星医药“明星”抗凝药新剂型获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2591594657","media":"北京药研汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591594657?lang=zh_cn&edition=full","pubTime":"2025-12-14 08:01","pubTimestamp":1765670477,"startTime":"0","endTime":"0","summary":"在国内，拜耳的利伐沙班片于2009年3月获批上市，商品名为拜瑞妥。利伐沙班是目前中国唯一拥有儿童VET治疗及预防复发适应症的抗凝药物。目前，利伐沙班拥有片剂、颗粒剂、口崩片及干混悬剂4种制剂获批上市。截至目前为止，利伐沙班干混悬剂原研尚未在国内上市。此次，桂林南药申报的利伐沙班干混悬剂成功获批上市，为本品首仿+首家过评。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251214081218a69f8716&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251214081218a69f8716&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","BK1515","02196","BK1593"],"gpt_icon":0},{"id":"2591865613","title":"辉瑞斥资“20亿美元”锁定“复星医药”口服GLP-1减重药全球权益","url":"https://stock-news.laohu8.com/highlight/detail?id=2591865613","media":"动脉网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591865613?lang=zh_cn&edition=full","pubTime":"2025-12-14 00:01","pubTimestamp":1765641660,"startTime":"0","endTime":"0","summary":"12月9日晚，复星医药公告其控股子公司与辉瑞签订《许可协议》，将自主研发的口服GLP-1R激动剂YP05002的全球独家开发、生产及商业化权利授予辉瑞，交易总价值最高达20.85亿美元，创国产口服GLP-1出海规模新高。YP05002是复星医药自主研发的口服小分子GLP-1R激动剂，主要瞄准代谢领域相关疾病，已在澳大利亚进入I期临床试验阶段。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251214013031a447bcc8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251214013031a447bcc8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02196","BK1191","BK1515","BK1593"],"gpt_icon":0},{"id":"2591656834","title":"昊海生科切入生物羊膜赛道","url":"https://stock-news.laohu8.com/highlight/detail?id=2591656834","media":"动脉网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591656834?lang=zh_cn&edition=full","pubTime":"2025-12-13 18:35","pubTimestamp":1765622100,"startTime":"0","endTime":"0","summary":"2025年12月13日，昊海生科发布公告，拟受让瑞济生物19.8%股权，切入生物羊膜赛道。昊海生科及独立第三方钟晓燕将分三阶段，以合计超4300万元受让瑞济生物部分股份，交易完成后昊海生科将持有其19.8%股份，资金来源为公司自有资金。瑞济生物成立于2002年，主营生物羊膜生产销售，产品用于骨科和眼科领域。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251214022510a69ee817&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251214022510a69ee817&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06826","BK1593","BK1161"],"gpt_icon":0},{"id":"2591630618","title":"复星医药：再次牵手MNC 创新转型持续推进","url":"https://stock-news.laohu8.com/highlight/detail?id=2591630618","media":"天风证券","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591630618?lang=zh_cn&edition=full","pubTime":"2025-12-13 00:00","pubTimestamp":1765555200,"startTime":"0","endTime":"0","summary":"事件12 月9 日，复星医药公告，其控股子公司药友制药与辉瑞签订《许可协议》，授予辉瑞口服小分子GLP-1R 激动剂YP05002 及含有该活性成分的产品在全球范围内独家开发、使用、生产及商业化权利。2025 年已完成3 笔license-out 交易，创新转型持续推进复星医药向Sitala 授予FXS6837 全球权益，取得首付款2500 万美元，潜在总金额6.70 亿美元。本次与辉瑞的交易，是复星医药2025 年完成的第三笔交易，且交易对手方的体量和交易规模大幅度提升，再次证实公司创新转型的决心及成果。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251213141623a446516e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251213141623a446516e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02196","BK1191","BK1593","BK1515"],"gpt_icon":0},{"id":"2590504257","title":"复星医药（600196）披露控股子公司药品注册申请获受理，12月12日股价下跌0.91%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590504257","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590504257?lang=zh_cn&edition=full","pubTime":"2025-12-12 22:07","pubTimestamp":1765548445,"startTime":"0","endTime":"0","summary":"截至2025年12月12日收盘，复星医药报收于28.28元，较前一交易日下跌0.91%，最新总市值为755.2亿元。该股当日开盘28.5元，最高28.59元，最低28.01元，成交额达5.67亿元，换手率为0.95%。近日，上海复星医药（集团）股份有限公司发布公告称，其控股子公司复宏汉霖就斯鲁利单抗注射液新增适应症的药品注册申请获国家药监局受理，并纳入优先审评程序。本次注册申请获受理不会对本集团现阶段业绩产生重大影响，后续仍需获得药品注册批准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121200040751.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK1593","BK0012","BK0028","BK0187","BK0239","BK0188","600196","BK0183","BK1515","BK0196","02196","BK0096","BK0175","BK1191"],"gpt_icon":0},{"id":"2590506694","title":"昊海生物科技(06826)拟收购江西瑞济生物工程技术股份有限公司约19.8%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2590506694","media":"智通财经","labels":["shareholding","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590506694?lang=zh_cn&edition=full","pubTime":"2025-12-12 20:32","pubTimestamp":1765542721,"startTime":"0","endTime":"0","summary":"智通财经APP讯，昊海生物科技 公布，于2025年12月12日，该公司及钟晓燕拟分别收购江西瑞济生物工程技术股份有限公司约19.8%及2.4554%的股权，代价分别约3835.15万元、475.6万元。目标公司的产品主要应用于骨科及眼科领域，用于肌腱损伤修复、眼表烧伤、创面及损伤病变修复以及泪道阻塞探通后植入及支撑。同时，目标公司所持有的羊膜材料具备人源生物特性，为集团在再生医学与组织工程领域提供了关键技术与材料基础，有望驱动后续产品创新与技术升级。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1381119.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1593","BK1161","06826"],"gpt_icon":0},{"id":"2590850524","title":"昊海生物科技(06826)：黎映彤获委任为联席公司秘书、授权代表及法律程序代理人","url":"https://stock-news.laohu8.com/highlight/detail?id=2590850524","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590850524?lang=zh_cn&edition=full","pubTime":"2025-12-12 20:11","pubTimestamp":1765541474,"startTime":"0","endTime":"0","summary":"智通财经APP讯，昊海生物科技(06826)发布公告，赵明璟先生已辞任公司其中一位联席公司秘书;根据香港联交所证券上市规则第3.05条所规定的公司的授权代表;及根据上市规则第19A.13(2)条及公司条例(香港法例第622章 )第16部所规定的代公司于香港接受法律程序送达文件及通知书的公司的授权代表，自2025年12月12日起生效。继赵先生辞任后，董事会欣然宣布，黎映彤女士，彼具备上市规则第3.28条所规定的专业资格，已获委任为联席公司秘书、授权代表及法律程序代理人，自2025年12月12日起生效。田敏女士将继续担任另一位联席公司秘书。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1381101.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1593","BK1161","06826"],"gpt_icon":0},{"id":"2590572747","title":"现代牙科(03600)：邱家宝将获委任为董事会薪酬委员会主席及提名委员会成员","url":"https://stock-news.laohu8.com/highlight/detail?id=2590572747","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590572747?lang=zh_cn&edition=full","pubTime":"2025-12-12 17:49","pubTimestamp":1765532991,"startTime":"0","endTime":"0","summary":"智通财经APP讯，现代牙科(03600)发布公告，由于张伟民博士有意投放更多时间于FDI世界牙医联盟(FDI World Dental Federation)的其他工作，彼于其现有任期届满后将不会续任公司的独立非执行董事一职。因此，张博士将于2025年12月15日，不再担任独立非执行董事、董事会薪酬委员会主席及提名委员会成员。于张博士退任后，公司的独立非执行董事邱家宝医生将获委任为董事会薪酬委员会主席及提名委员会成员。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1380953.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK1100","03600","BK1593"],"gpt_icon":0},{"id":"2590572449","title":"复星医药(600196.SH)：斯鲁利单抗注射液新增适应症药品注册申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2590572449","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590572449?lang=zh_cn&edition=full","pubTime":"2025-12-12 17:38","pubTimestamp":1765532312,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药 发布公告，近日，公司控股子公司上海复宏汉霖生物技术股份有限公司及其控股子公司就斯鲁利单抗注射液新增适应症的药品注册申请获国家药品监督管理局受理，并已获纳入优先审评程序。该药品为集团自主研发的创新型抗PD-1单抗。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1380944.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0183","BK0239","BK0060","600196","02196","BK0187","BK1593","BK0175","BK0096","BK1515","BK0188","BK0012","BK0196","BK0028","BK1191"],"gpt_icon":0},{"id":"2590506572","title":"复星医药(600196.SH)：酮洛芬贴剂获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2590506572","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590506572?lang=zh_cn&edition=full","pubTime":"2025-12-12 17:32","pubTimestamp":1765531926,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药(600196.SH)发布公告，近日，公司控股子公司上海朝晖药业有限公司(以下简称“朝晖药业”)收到国家药品监督管理局(以下简称“国家药监局”)关于同意酮洛芬贴剂(以下简称“该药品”)开展临床试验的批准。朝晖药业拟于条件具备后于中国境内1开展该药品的Ⅲ期临床试验。更多港股重磅资讯，下载智通财经app更多港股及海外理财资讯，请点击www.zhitongcaijing.com（搜索“智通财经”）；欲加入智通港股投资群，请加智通客服微信(ztcjkf)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1380936.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1191","BK0175","BK0012","BK1515","BK0188","BK0239","600196","BK0060","BK0028","BK1593","02196","BK0196","BK0183","BK0096","BK0187"],"gpt_icon":0},{"id":"2590050385","title":"每日卖空追踪 | 现代牙科 12月12日卖空量成交1.5万股，卖空比例为1.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590050385","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590050385?lang=zh_cn&edition=full","pubTime":"2025-12-12 16:30","pubTimestamp":1765528232,"startTime":"0","endTime":"0","summary":"现代牙科北京时间12月12日，涨4.38%，卖空量成交1.5万股，较上一交易日减少67.39%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251212165614a4446cf2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251212165614a4446cf2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","BK1100","BK1593","03600"],"gpt_icon":0},{"id":"2591686673","title":"每日卖空追踪 | 三生制药 12月12日卖空量成交57.9万股，卖空比例为2.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2591686673","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591686673?lang=zh_cn&edition=full","pubTime":"2025-12-12 16:30","pubTimestamp":1765528220,"startTime":"0","endTime":"0","summary":"三生制药北京时间12月12日，涨0.94%，卖空量成交57.9万股，较上一交易日减少55.01%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025121216494295398b3f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025121216494295398b3f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1593","BK1161","HK0000165453.HKD","01530","BK1583"],"gpt_icon":0},{"id":"2591633807","title":"四环医药12月12日获主力加仓593.7万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2591633807","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591633807?lang=zh_cn&edition=full","pubTime":"2025-12-12 16:16","pubTimestamp":1765527360,"startTime":"0","endTime":"0","summary":"12月12日, 四环医药股价涨1.55%，报收1.31元，成交金额3432.3万元，换手率0.29%，振幅2.33%，量比1.55。四环医药今日主力资金净流入593.7万元，连续3日净流入，上一交易日主力净流入245.9万元。近一年数据显示，该股主力连续3日净流入后，次日上涨概率为40.00%，平均涨幅为5.01%。该股近5个交易日下跌0.75%，主力资金累计净流入861.6万元；近20日主力资金累计净流入386.0万元，其中净流入天数为10日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025121216292995398200&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025121216292995398200&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1593","BK1191","00460","BK1600","BK1515"],"gpt_icon":0}],"profile":{"compareEarnings":[{"period":"1week","weight":-0.0042},{"period":"1month","weight":-0.0351},{"period":"3month","weight":-0.0156},{"period":"6month","weight":0.0872},{"period":"1year","weight":0.2736},{"period":"ytd","weight":0.295}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"name":"BK1593","nameEN":"BK1593"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"医美概念股(BK1593)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供医美概念股(BK1593)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"医美概念股,BK1593,医美概念股股票,医美概念股股票老虎,医美概念股股票老虎国际,医美概念股行情,医美概念股股票行情,医美概念股股价,医美概念股股市,医美概念股股票价格,医美概念股股票交易,医美概念股股票购买,医美概念股股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"医美概念股(BK1593)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供医美概念股(BK1593)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}